Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety

The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.